Publication | Closed Access

Phillyrin attenuates norepinephrine-induced cardiac hypertrophy and inflammatory response by suppressing p38/ERK1/2 MAPK and AKT/NF-kappaB pathways

InflammationAnti-inflammatoryMolecular PhysiologyCardiovascular DiseaseMedicinePhysiologyInflammatory ResponseCardiovascular PharmacologyAkt/nf-kappab PathwaysNorepinephrine-induced Cardiac HypertrophyPharmacotherapyCardiovascular FunctionPharmacologyCardiology